Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela George

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 26, 2024
Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutationQuratul Ain, Rachel L O'Connell, Parinita Swarnkar, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Trials|February 2, 2024
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocolMiriam Dixon-Zegeye, Rachel Shaw, Linda Collins, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2021
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for <i>BRCA</i>1/2 variants in ovarian cancer in the United KingdomSudha Sundar, Ranjit Manchanda, Charlie Gourley, et al.
Journal of Medical Genetics|March 13, 2025
Uptake, utility and resource requirements of a genetic counselling telephone helpline within the BRCA-DIRECT digital pathway for mainstreamed BRCA testing in patients with breast cancerBethany Torr, Grace Kavanaugh, Monica Hamill, et al.
JAMA Oncology|March 17, 2023
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical TrialSusana Banerjee, Gaia Giannone, Andrew R Clamp, et al.
NPJ Breast Cancer|July 9, 2026
Routine germline genetic testing in 3552 unselected NHS breast cancer patients: evidence informing testing criteria and implementation of a 'BRCA-DIRECT' mainstreaming pathwayBethany Torr, Lea Mansour, Caitlin T Fierheller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancerAlejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Journal of Medical Genetics|December 23, 2024
The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024)Bethany Torr, Nicola Bell, Ruth McCarthy, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 26, 2024
Breast cancer outcomes in women with ovarian cancer and a pathogenic germline BRCA mutationQuratul Ain, Rachel L O'Connell, Parinita Swarnkar, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Trials|February 2, 2024
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocolMiriam Dixon-Zegeye, Rachel Shaw, Linda Collins, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2021
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for <i>BRCA</i>1/2 variants in ovarian cancer in the United KingdomSudha Sundar, Ranjit Manchanda, Charlie Gourley, et al.
Journal of Medical Genetics|March 13, 2025
Uptake, utility and resource requirements of a genetic counselling telephone helpline within the BRCA-DIRECT digital pathway for mainstreamed BRCA testing in patients with breast cancerBethany Torr, Grace Kavanaugh, Monica Hamill, et al.
JAMA Oncology|March 17, 2023
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical TrialSusana Banerjee, Gaia Giannone, Andrew R Clamp, et al.
NPJ Breast Cancer|July 9, 2026
Routine germline genetic testing in 3552 unselected NHS breast cancer patients: evidence informing testing criteria and implementation of a 'BRCA-DIRECT' mainstreaming pathwayBethany Torr, Lea Mansour, Caitlin T Fierheller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancerAlejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Journal of Medical Genetics|December 23, 2024
The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023-2024)Bethany Torr, Nicola Bell, Ruth McCarthy, et al.
Pageof 5